Načítá se...
Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells
BACKGROUND: Omalizumab, is a humanized anti-IgE monoclonal antibody used to treat allergic asthma. Decreased serum IgE levels, lower eosinophil and B cell counts have been noted as a result of treatment. In vitro studies and animal models support the hypothesis that omalizumab inhibits IgE synthesis...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3875359/ https://ncbi.nlm.nih.gov/pubmed/24004581 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2045-7022-3-29 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|